TY - JOUR
T1 - Genome-wide plasma cell-free DNA methylation profiling identifies potential biomarkers for lung cancer
AU - Xu, Wei
AU - Lu, Jun
AU - Zhao, Qiang
AU - Wu, Jun
AU - Sun, Jielin
AU - Han, Baohui
AU - Zhao, Xiaodong
AU - Kang, Yani
N1 - Publisher Copyright:
Copyright © 2019 Wei Xu et al.
PY - 2019
Y1 - 2019
N2 - As a noninvasive blood testing, the detection of cell-free DNA (cfDNA) methylation in plasma has raised an increasing interest due to diagnostic applications. Although extensively used in cfDNA methylation analysis, bisulfite sequencing is less cost-effective. In this study, we investigated the cfDNA methylation patterns in lung cancer patients by MeDIP-seq. Compared with the healthy individuals, 330 differentially methylated regions (DMRs) at gene promoters were identified in lung cancer patients with 33 hypermethylated and 297 hypomethylated regions, respectively. Moreover, these hypermethylated genes were validated with the publicly available DNA methylation data, yielding a set of ten significant differentially methylated genes in lung cancer, including B3GAT2, BCAR1, HLF, HOPX, HOXD11, MIR1203, MYL9, SLC9A3R2, SYT5, and VTRNA1-3. Our study demonstrated MeDIP-seq could be effectively used for cfDNA methylation profiling and identified a set of potential biomarker genes with clinical application for lung cancer.
AB - As a noninvasive blood testing, the detection of cell-free DNA (cfDNA) methylation in plasma has raised an increasing interest due to diagnostic applications. Although extensively used in cfDNA methylation analysis, bisulfite sequencing is less cost-effective. In this study, we investigated the cfDNA methylation patterns in lung cancer patients by MeDIP-seq. Compared with the healthy individuals, 330 differentially methylated regions (DMRs) at gene promoters were identified in lung cancer patients with 33 hypermethylated and 297 hypomethylated regions, respectively. Moreover, these hypermethylated genes were validated with the publicly available DNA methylation data, yielding a set of ten significant differentially methylated genes in lung cancer, including B3GAT2, BCAR1, HLF, HOPX, HOXD11, MIR1203, MYL9, SLC9A3R2, SYT5, and VTRNA1-3. Our study demonstrated MeDIP-seq could be effectively used for cfDNA methylation profiling and identified a set of potential biomarker genes with clinical application for lung cancer.
UR - https://www.scopus.com/pages/publications/85062843097
U2 - 10.1155/2019/4108474
DO - 10.1155/2019/4108474
M3 - 文章
C2 - 30867848
AN - SCOPUS:85062843097
SN - 0278-0240
VL - 2019
JO - Disease Markers
JF - Disease Markers
M1 - 4108474
ER -
